Anavex Life Sciences Corp. Stock News

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q4 2022 Earnings Conference Call November 28, 2022 8:30 AM ET Company Participants Clint Tomlinson - IR Dr. Christopher Missling - President and CEO Sandra Bo

Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ET Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ET

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is a "very early stage company that has a lot in the pipe. I tend to like these companies." Analysts

Anavex will present results from its phase 2b/3 trial for blarcamesine for Alzheimer's disease at the CTAD conference in San Francisco on December 1st. A past trial suggests that Anavex's blarcamesine

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie

Anavex has two big catalysts coming up, both in Alzheimer's disease and Parkinson's Disease Dementia. Results reported so far show long-lasting cognition changes, and I am expecting Anavex to report i

Treatments such as Aricept and likely simufilam that inhibit the formation of the nitro-oxidant peroxynitrite and speed its decomposition stabilize Alzheimer's disease for about a year. Treatments (bl

Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1

Recent research is claiming pivotal study data was falsified in order to bolster the amyloid hypothesis. This should have a positive impact on Alzheimer's programs based on other mechanisms.

AVXL earnings call for the period ending June 30, 2022.

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q3 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Clint Tomlinson - IR Dr. Christopher Missling - President and CEO Sandra Boenis

Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET

Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET

ANAVEX®3-71 effect is supported by biomarkers: Decrease of extracellular A (Abeta) deposition and reduced pathological inflammatory glial cell recruitment towards hippocampal neurons (p ≤ 0.01) ANA

Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer’s and Parkinson’s disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p<0.005)